Deficit psychopathology and a paradigm shift in schizophrenia research

Biological Psychiatry

Volumn 46, Issue 3, 1999, Pages 352-360

  Carpenter Jr , William T ^a   Arango, Celso ^a   Buchanan, Robert W ^a   Kirkpatrick, Brian ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Deficit syndrome; Heterogeneity; Negative symptoms; Schizophrenia; Treatment

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE CLASSIFICATION; FACTORIAL ANALYSIS; HEREDITY; HUMAN; MENTAL DISEASE; NEGATIVE SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

AFFECT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0344673598     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00088-8     Document Type: Review

References (74)

1. Andreasen N.C., Olsen S.A. Negative vs. positive schizophrenia: definition and validation. Arch Gen Psychiatry. 39:1982;789-794.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 7:(Suppl):1989;49-58.
3. Arndt S., Alliger R.J., Andreasen N.C. The distinction of positive and negative symptoms: the failure of a two-dimensional model. Br J Psychiatry. 158:1991;317-322.
4. Arango C, Adami H, Sherr J, Thaker G, Carpenter WT (in press). Awareness of mental illness and dyskinesia in schizophrenia. Am J Psychiatry.
5. Arolt V., Lencer R., Nolte A., Muller-Myhsok B., Purmann S., Schurmann M., Leutelt J., Pinnow M., Schwinger E. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am J Med Genet. 67:1996;564-579.
6. Beratis S., Gabriel J., Hoidas S. Age at onset in subtypes of schizophrenic disorders. Schizophr Bull. 20:1994;287-296.
7. Bilder R.M., Mukherjee S., Rieder R.O., Pandurangi A.K. Symptomatic and neuropsychological components of defect states. Schizophr Bull. 11:1985;409-419.
8. Bleuler E (1952): Dementia Praecox or The Group of Schizophrenias. Translated by Joseph Zinkin. Monograph series on schizophrenia, No. 1. New York, International Universities Press.
9. Breier A., Buchanan R.W., Kirkpatrick B., Davis O.R., Irish D., Summerfelt A., Carpenter W.T. Jr. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
10. Buchanan R.W., Kirkpatrick B., Heinrichs D.W., Carpenter W.T. Jr. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 147:1990;290-294.
11. Buchanan R.W., Breier A., Kirkpatrick B., Elkashef A., Munson R.C., Gellad F., Carpenter W.T. Jr. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry. 150:1993;59-65.
12. Buchanan R.W., Carpenter W.T. Jr. Domains of psychopathology. An approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis. 182:1994;193-204.
13. Buchanan R.W., Strauss M.E., Kirkpatrick B., Holstein C., Breier A., Carpenter W.T. Jr. Neuropsychological impairments in deficit vs. nondeficit forms of schizophrenia. Arch Gen Psychiatry. 51:1994;804-811.
14. Buchanan R.W., Gold J.M. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol. 11:(Suppl 2):1996;3-11.
15. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 155:1998;751-760.
16. Bustillo J.R., Thaker G., Buchanan R.W., Moran M., Kirkpatrick B., Carpenter W.T. Jr. Visual information-processing impairments in deficit and nondeficit schizophrenia. Am J Psychiatry. 154:1997;647-654.
17. Carpenter W.T., Bartko J.J., Langsner C.A., Strauss J.S. Another view of schizophrenic subtypes: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 33:1976;508-516.
18. Carpenter W.T. Jr, Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 145:1988;578-583.
19. Carpenter W.T. Jr, Buchanan R.W. Domains of psychopathology relevant to the study of etiology and treatment in schizophrenia. Schulz S.C., Tamminga C.A. Schizophrenia Scientific Progress . 1989;Oxford Press, New York.
20. Carpenter W.T. Jr, Strauss J.S. The prediction of outcome in schizophrenia. IV: Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis. 179:1991;517-525.
21. Carpenter W.T. Psychopathology and common sense: where we went wrong with negative symptoms (editorial). Biol Psychiatry. 29:1991;735-737.
22. Carpenter W.T. Arch Gen Psychiatry. 49:1992;236-237.
23. Carpenter W.T. Jr, Buchanan R.W., Kirkpatrick B., Tamminga C., Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry. 50:1993;825-831.
24. Carpenter W.T. Jr. The deficit syndrome (editorial). Am J Psychiatry. 151:1994;327-329.
25. Conley R., Richardson C., Kent D., Gounaris C., Zaremba S. Clozapine response varies in deficit vs. non-deficit schizophrenic subjects. Biol Psychiatry. 35:1994;746.
26. Carpenter W.T. Jr, Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry. 152:1995;827-832.
27. Carpenter W.T. Jr, Conley R.R., Buchanan R.W., Breier A., Tamminga C.A. Clozapine conflict. Am J Psychiatry. 153:1996;1505-1507.
28. Conley R.R., Buchanan R.W. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 23:1997;663-667.
29. Crow T.J. Molecular pathology of schizophrenia: more than one disease process? Br Med J. 280:1980;66-68.
30. Crow T.J. The two-syndrome concept origins and current status . Schizophr Bull. 11:1985;571-586.
31. Dollfus S., Ribeyre J.M., Petit M. Family history and deficit form in schizophrenia. Eur Psychiatry. 11:1996;260-267.
32. Engel G.E. The need for a new medical model: a challenge for biomedicine. Science. 196:1977;129-136.
33. Fenton W.S., McGlashan T.H. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry. 49:1992;179-184.
34. Fenton W.S., McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry. 151:1994;351-356.
35. Fenton W.S., Wyatt R.J., McGlashan T.H. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry. 51:1994;643-650.
36. Fenton W.S., McGlashan T.H., Victor B.J., Blyler C.R. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry. 154:1997;199-204.
37. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA. 94:1997;587-592.
38. Frith C.F. The Cognitive Neuropsychology of Schizophrenia. Essays in Cognitive Psychology. 1992;Lawrence Erlbaum Associates, Hove, UK.
39. Frith C. Neuropsychology of schizophrenia, what are the implications of intellectual and experiential abnormalities for the neurobiology of schizophrenia? Br Med Bull. 52:1996;618-626.
40. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 153:1996;1628-1630.
41. Goldberg S.C. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull. 11:1985;453-456.
42. Griesinger W (1965): Mental Pathology and Therapeutics. A facsimile of the English edition of 1867. New York Academy of Medicine. New York: Hafner.
43. Hawk A.B., Carpenter W.T., Strauss J.S. Diagnostic criteria and 5-year outcome in schizophrenia: A report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry. 32:1975;343-356.
44. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
45. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 13:1987;261-276.
46. Kendler K.S., McGuire M., Gruenberg A.M., Walsh D. Outcome and family study of the subtypes of schizophrenia in the west of Ireland. Am J Psychiatry. 151:(6):1994;849-856.
47. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. Jr. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res. 30:1989;119-124.
48. Kirkpatrick B., Buchanan R.W., Breier A., Carpenter W.T. Jr. Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis. 182:1994;452-455.
49. Kirkpatrick B., Carpenter W.T. Jr. Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry. 38:1995;277-278.
50. Kirkpatrick B., Amador X.F., Yale S.A., Bustillo J.R., Buchanan R.W., Tohen M. The deficit syndrome in the DSM-IV field trial. Depressive episodes and persecutory beliefs. Schizophr Res. 20:1996;79-90.
51. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T. Jr, Tohen M., McGlashan T. The deficit syndrome in the DSM-IV field trial. Alcohol and other drug abuse. Schizophr Res. 20:1996;76-68.
52. Kirkpatrick B., Ram R., Bromet E. The deficit syndrome in the Suffolk County mental health project. Schizophr Res. 22:1996;119-126.
53. Kirkpatrick B., Ram R., Amador X.F., Buchanan R.W., McGlashan T., Tohen M., Bromet E. Summer birth and the deficit syndrome of schizophrenia. Am J Psychiatry. 155:1998;1221-1226.
54. Kirkpatrick B, Conley RC, Kakoyannis, Reep RL, Roberts RC (in press): The interstitial cells of the white matter in the inferior parietal cortex in schizophrenia: an unbiased cell-counting study. Synapse.
55. Kirkpatrick B, Castle D, Murray RM, Carpenter WT Jr (in press): Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull.
56. Kraepelin E. Dementia Praecox and Paraphrenia (original work published 1919). 1971;Krieger, New York.
57. Lahti A.C., Holcomb H.H., Carpenter W.T., Zhao M., Buchanan R.W., Tamminga C.A. Blood flow activation differences during an auditory task in schizophrenic patients with and without primary negative symptoms. Schizophr Res. 24:1997;167.
58. Liddle P.F. The symptoms of chronic schizophrenia a reexamination of the positive-negative dichotomy . Br J Psychiatry. 151:1987;145-151.
59. Liddle P.F., Barnes T.R., Morris D., Haque S. Three syndromes in chronic schizophrenia. Br J Psychiatry. 7:(Suppl):1989;119-122.
60. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 160:1992;179-186.
61. McGlashan T.H., Fenton W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr Bull. 19:1993;71-84.
62. Meltzer H.Y., Sommers A.A., Luchins D.J. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol. 6:1986;329-338.
63. Ross D.E., Thaker G.K., Buchanan R.W., Lahti A.C., Medoff D., Bartko J.J., Moran M., Hartley J. Association of abnormal smooth pursuit eye movement with the deficit syndrome in schizophrenic patients. Am J Psychiatry. 153:1996;1158-1165.
64. Ross D.E., Thaker G.K., Buchanan R.W., Kirkpatrick B., Lahti A.C., Medoff D., Bartko J.J., Goodman J., Tien A. Eye tracking disorder in schizophrenia is characterized by specific ocular motor defects and is associated with the deficit syndrome. Biol Psychiatry. 42:1997;781-796.
65. Shenton M.E., Kikinis R., Jolesz F.A., Pollak S.D., LeMay M., Wible C.G., Hokama H., Martin J., Metcalf D., Coleman M., et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Eng J Med. 327:1992;604-612.
66. Strauss J.S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia. Part II: speculations on the process that underlie schizophrenic symptoms and signs . Schizophr Bull. 11:1974;61-69.
67. Strauss J.S., Carpenter W.T. Schizophrenia. 1981;Plenum Press, New York.
68. Summerfelt A.T., Buchanan R.W., Breier A., Bryant N., Strauss M.E. The relationships of cerebellar vermis morphology to neuropsychological functions in schizophrenia and normal controls. Schizophr Res. 15:1995;136.
69. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 49:1992;522-530.
70. Thaker G., Kirkpatrick B., Buchanan R.W., Ellsberry R., Lahti A., Tamminga C. Oculomotor abnormalities and their clinical correlates in schizophrenia. Psychopharmacol Bull. 25:1989;491-497.
71. Vita A., Dieci M., Giobbio G.M., Caputo A., Ghiringhelli L., Comazzi M., Garbarini M., Mendini A.P., Morganti C., Tenconi F., et al. Language and thought disorder in schizophrenia: brain morphological correlates. Schizophr Res. 15:1995;243-251.
72. Waltrip R.W. 2nd, Buchanan R.W., Carpenter W.T. Jr, Kirkpatrick B., Summerfelt A., Breier A., Rubin S.A., Carbone K.M. Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res. 23:1997;253-258.
73. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
74. Report of the International Pilot Study of Schizophrenia. Vol. 1:1974;WHO Press, Geneva, Switzerland.